EUVIMEDSkopri EUVIMED
Crossref

Sirolimus Plus Low‐Exposure Calcineurin Inhibitors as an Alternative Graft‐Versus‐Host Disease Prophylaxis in Calcineurin Inhibitor‐Intolerant Recipients: A Retrospective Study

Yanfei Lu iD, Min Wu, Zhenbin Wei, Lingling Shi, Yongrong Lai, Rongrong Liu

Clinical Transplantation · 2025

DOI: 10.1111/ctr.70306 ↗

At a glance

Journal article in Clinical Transplantation, 2025. Written by Yanfei Lu and 5 co-authors. Institution: Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China. Major MEDLINE topics: Graft vs Host Disease, Calcineurin Inhibitors, Sirolimus, Hematopoietic Stem Cell Transplantation. 35 references.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Graft‐versus‐host disease (GvHD) remains a major barrier to long‐term survival after allogeneic hematopoietic stem cell transplantation (allo‐HSCT). Although calcineurin inhibitors (CNIs) are the cornerstone of GvHD prophylaxis, some patients cannot tolerate them, creating a critical need for alternative strategies.

Objective

To evaluate the efficacy and safety of sirolimus plus low‐exposure CNIs as an alternative GvHD prophylaxis in CNI‐intolerant recipients undergoing allo‐HSCT.

Methods

We retrospectively analyzed 16 allo‐HSCT recipients who received alternative GvHD prophylaxis due to CNI intolerance, evaluating GvHD incidence, survival and relapse outcomes, infectious complications, and immune reconstitution.

Results

The median time to regimen initiation was 27.5 days (range, −2 to 114 days), and the median treatment duration was 53 days (range, 14–319 days). Only one patient (6.3%) experienced grade 2 acute GvHD, and none developed grade 3–4 acute GvHD. No cases of chronic GvHD were observed in the 15 evaluable patients. Over a median follow‐up of 271 days (range, 58–505 days), one non‐relapse mortality and three relapses (18.7%) occurred, with no relapse‐related deaths. The alternative regimen was well‐tolerated with manageable infections and, importantly, did not impair early T, B, or NK cell reconstitution.

Conclusion

For allo‐HSCT recipients with CNI intolerance, this study provides the first evaluation of sirolimus combined with low‐exposure CNIs as a GvHD prophylaxis. Our findings suggest this regimen is a promising and feasible alternative, although validation in larger, prospective studies is warranted.

Subjects

MeSH terms (MEDLINE)

Graft vs Host DiseaseCalcineurin InhibitorsSirolimusHematopoietic Stem Cell TransplantationImmunosuppressive AgentsHumansRetrospective StudiesMaleFemaleMiddle AgedAdultFollow-Up StudiesPrognosisYoung AdultSurvival RateRisk FactorsGraft SurvivalAdolescentAged

Author keywords

allogeneic hematopoietic stem cell transplantationcalcineurin inhibitorgraft versus host diseasesirolimus

Substances

Calcineurin InhibitorsSirolimusImmunosuppressive Agents

Authors and institutions

  • Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
  • Department of Oncology, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, China.
  • NHC Key Laboratory of Thalassemia Medicine, Nanning, Guangxi, China.
  • Guangxi Key Laboratory of Thalassemia Research, Nanning, Guangxi, China.

ORCID profiles: Yanfei Lu

Cite

APA

Lu, Y., Wu, M., Wei, Z., Shi, L., Lai, Y., & Liu, R. (2025). Sirolimus Plus Low‐Exposure Calcineurin Inhibitors as an Alternative Graft‐Versus‐Host Disease Prophylaxis in Calcineurin Inhibitor‐Intolerant Recipients: A Retrospective Study. Clinical Transplantation. https://doi.org/10.1111/ctr.70306

Vancouver

Lu Y, Wu M, Wei Z, Shi L, Lai Y, Liu R. Sirolimus Plus Low‐Exposure Calcineurin Inhibitors as an Alternative Graft‐Versus‐Host Disease Prophylaxis in Calcineurin Inhibitor‐Intolerant Recipients: A Retrospective Study. Clinical Transplantation. 2025. doi:10.1111/ctr.70306

BibTeX
@article{Lu2025,
  author = {Lu, Yanfei and Wu, Min and Wei, Zhenbin and Shi, Lingling and Lai, Yongrong and Liu, Rongrong},
  title = {Sirolimus Plus Low‐Exposure Calcineurin Inhibitors as an Alternative Graft‐Versus‐Host Disease Prophylaxis in Calcineurin Inhibitor‐Intolerant Recipients: A Retrospective Study},
  journal = {Clinical Transplantation},
  year = {2025},
  doi = {10.1111/ctr.70306}
}
Start for free →